Bumper crop of new drugs fails to lift big pharma R&D returns

LONDON, Dec 14 (Reuters) - It is shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.